Form 4: Applied Therapeutics Director Jay Skyler S Acquires 45,000 Shares of Common Stock

Director Jay Skyler S acquired 45,000 shares of Applied Therapeutics common stock on June 6, 2024, as part of a compensatory Restricted Stock Unit grant.

Summary

• On June 6, 2024, Jay Skyler S, a director of Applied Therapeutics, Inc. (APLT), acquired 45,000 shares of common stock.
• The acquisition was part of a compensatory Restricted Stock Unit (RSU) grant under the company's 2019 Equity Incentive Plan.
• The price per share for the acquisition was $0.00.
• Following the transaction, Skyler's direct ownership of Applied Therapeutics common stock is 65,000 shares.
• The RSUs vest quarterly from June 6, 2024, until the earlier of the first anniversary of the grant date or the date of the issuer's next annual stockholder meeting, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally a good sign, indicating confidence in the company. However, it's a standard compensation practice, so the impact is moderate.

Positives

• The acquisition of shares by a director signals confidence in the company's future prospects.
• The vesting schedule of the RSUs incentivizes the director to remain with the company.

Future Outlook

The vesting schedule of the RSUs suggests a commitment from the director to remain with the company for at least one year, or until the next annual stockholder meeting.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as a way to align management's interests with those of shareholders. These grants are part of a broader compensation strategy to attract and retain key personnel.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen use similar equity incentive plans to align the interests of their executives and directors with those of shareholders.
• The size of the grant is typical for director-level compensation in companies of similar market capitalization.

Stakeholder Impact

• Shareholders may view the director's stock acquisition positively, as it aligns the director's interests with theirs.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates